Get startedLog in
    Picture of Hofseth Biocare ASA logo

    HBC — Hofseth Biocare ASA News Story

    0.000.00%
    no flag iconLast trade - 00:00
    Consumer DefensivesSpeculativeMicro CapSucker Stock
    All News

    Norway's Hofseth Biocare Q4 revenue rises on Human Nutrition demand

    Picture of Hofseth Biocare ASA logoHofseth Biocare ASA
    13/02/2026 07:23
    Overview

Norwegian consumer health firm's Q4 revenue rose yr/yr

Human Nutrition B2B revenues increased 300% yr/yr, driven by strong demand

Company raised NOK 158 mln in private placement, sold stake in AecorBio Inc.

Outlook

Company expands regulatory access with ingredient approvals in Australia and South Korea

HBC raised NOK 158 mln in private placement to support growth and R&D

Company sees strong demand for ProGo® and CalGo® driving revenue growth

Result Drivers

HUMAN NUTRITION GROWTH - Human Nutrition B2B revenues increased by 300% yr/yr, driven by strong demand for ProGo® and CalGo®

REGULATORY EXPANSION - Expanded regulatory access with ingredient approvals in Australia and South Korea, opening large markets

PET NUTRITION IMPROVEMENT - Pet Nutrition B2B volumes and revenues improved, supported by increased customer engagement and trade-show activity

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q4 RevenueNOK 72.20 mln
    Q4 EBITDA-NOK 26.50 mln
    

Press Release: ID:nGNEBBcFl

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Hofseth Biocare ASA

    See all news